Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share. This investment by Teva was made pursuant to the terms of the Securities Purchase Agreement, dated June 26, 2009, as amended. The investment money will be used for the purpose of supporting the research and development program for the pre-clinical stage, anti-cancer compound RX-3117. After this transaction, Teva will own 6.29% of the outstanding shares of Rexahn.

“We are also pleased with RX-3117's development to date, and we are working to advance the compound into clinical trials in 2011.”

"We are excited by Teva's increased commitment to this collaboration and the development of RX-3117," said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer. "We are also pleased with RX-3117's development to date, and we are working to advance the compound into clinical trials in 2011."

Source:

 Rexahn Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study evaluates first tumor-uninformed ctDNA assay to detect residual cancer cells after treatment